Here are five highlights:
1. The company saw a 49 percent year-over-year growth rate at mid-year 2017.
2. nanoLOCK sales volume rose 42 percent since the end of the first quarter 2017.
3. Titan Spine reported 150 surgeons have used the nanoLOCK in 98 hospitals.
4. Surgeons have implanted 2,500 nanoLOCK implantations since its launch in 2016.
5. Surgeons have implanted more than 50,000 Endoskeleton interbody fusion devices since its launch.
More articles on devices:
K2M reports 10.9% Q2 revenue increase, $9.1M net loss: 7 things to know
Mazor Robotics sells 14 Mazor X systems in Q2, revenue jumps 87% to $15.5M: 7 things to know
InVivo Therapeutics reports INSPIRE study updates; reports one death unrelated to study — 5 things to know
